Nastech Pharmaceutical Company
Nastech Pharmaceutical Company Newswire

Nastech Pharmaceutical Company Newswire

Comprehensive Real-Time News Feed for Nastech Pharmaceutical Company.

Results 1 - 20 of 20 in Nastech Pharmaceutical Company

  1. Biotech Weekly: Taking A Pulse On Biotech And Speculating On SpeculationRead the original story w/Photo

    Monday Jun 22 | Seeking Alpha

    With a very active M&A environment, a period of substantial scientific innovation , and strong performance of small cap names, there is legitimacy to this biotech rally. I think bubble talk is heavily based on past stock performance, and bubble talk participants often use incorrect valuation metrics for both small cap bios and large cap bios.

    Comment?

  2. Marina Biotech, Inc. Expands European And Canadian Patent Protection...Read the original story

    Tuesday Jun 9 | BioSpace

    Marina Biotech, Inc. , a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the company has received a notice of allowance from the European Patent Office of the intent to grant the claims in EP 07856910.0 which broadly cover SMARTICLES amphoteric liposomes made with a wide range of novel sterol amphiphiles. In addition, the company has received a notice of allowance of Canada Patent 2,665,783, which covers processes for making a broad range of amphoteric liposomes, including the SMARTICLES formulation currently in Phase I and Phase II clinical studies.

    Comment?

  3. Marina Biotech, Inc. Announces First Quarter 2015 Financial ResultsRead the original story

    May 14, 2015 | BioSpace

    Marina Biotech, Inc. , a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported financial results for the three months ended March 31, 2015. Expanded U.S. patent protection for the company's TransKingdom RNAi technology with the issuance of US Pat.

    Comment?

  4. Marina Biotech Announces First Quarter 2015 Financial ResultsRead the original story

    May 14, 2015 | Freshnews

    Marina Biotech, Inc. , a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported financial results for the three months ended March 31, 2015. Expanded U.S. patent protection for the company's TransKingdom RNAi technology with the issuance of US Pat.

    Comment?

  5. Marina Biotech, Inc. Announces SMARTICLES-Mediated Delivery Of A...Read the original story

    May 5, 2015 | BioSpace

    Marina Biotech, Inc. , a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that its SMARTICLES delivery platform delivered a double-stranded miRNA mimic to white blood cells of patients with multiple tumor types, as announced by Mirna Therapeutics, Inc. Mirna reported that a molecular analysis of white blood cells from patients treated with MRX34 showed a dose dependent repression of several key oncogenes previously identified as direct miR-34 targets including FOXP1, BCL2, HDAC1 and CTNNB1. These data suggest delivery of miR-34 into human white blood cells and engagement of several biological targets of miR-34.

    Comment?

  6. Catabasis Names Ted Hibben SVP, Corporate DevelopmentRead the original story

    Apr 24, 2015 | Freshnews

    Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that it has named Ted Hibben as senior vice president, corporate development. Mr. Hibben brings to Catabasis over 20 years of experience in business and corporate development, strategy, fundraising and M&A.

    Comment?

  7. Marina Biotech, Inc. Expands Global Patent Protection Of Clinical...Read the original story

    Apr 22, 2015 | BioSpace

    Marina Biotech, Inc. , a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today it has expanded its U.S. patent protection for the company's TransKingdom RNAi technology and has been granted additional patent rights for its SMARTICLES and Di-terminal Amino Acid Lipids nucleic acid delivery technologies . Both the tkRNAi and SMARTICLES technologies support on-going clinical development programs.

    Comment?

  8. Marina Biotech Expands Global Patent Protection of Clinical Stage Nucleic Acid Delivery TechnologiesRead the original story

    Apr 23, 2015 | Freshnews

    Marina Biotech, Inc. , a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today it has expanded its U.S. patent protection for the company's TransKingdom RNAi technology and has been granted additional patent rights for its SMARTICLES and Di-terminal Amino Acid Lipids nucleic acid delivery technologies . Both the tkRNAi and SMARTICLES technologies support on-going clinical development programs.

    Comment?

  9. Rosetta Genomics Reports 2014 Financial ResultsRead the original story

    Mar 16, 2015 | Freshnews

    PRINCETON, N.J. & REHOVOT, Israel -- -- Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based molecular diagnostics, today reported financial results for the 12 months ended December 31, 2014.

    Comment?

  10. Rosetta Genomics Reports 2014 Financial ResultsRead the original story

    Mar 16, 2015 | Business Wire

    Showcased the Company's microRNA-based assay for thyroid cancer at the 84th Annual Meeting of the American Thyroid Association , on track to launch in the third quarter of 2015; Published data in the peer-reviewed journal Applied Immunohistochemistry and Molecular Morphology , which highlight the ability of microRNA profiles to differentiate adrenocortical carcinomas from adenomas, as well as their ability to identify malignancy in adrenocortical tumors ; Conducted the first clinical study to identify novel microRNA candidates for the treatment of Duchenne Muscular Dystrophy under a strategic alliance with Marina Biotech; Published a study in the Journal of Kidney Cancer that supports the use of the Rosetta Kidney Cancer Testa to accurately classify tumor subtypes in kidney cancers and be a potential driver of the reduction of unnecessary surgeries; Collaboration with Biocept, Inc. that ... (more)

    Comment?

  11. Marina Biotech, Inc. Provides 2014 Year-End Financials And UpdateRead the original story

    Feb 25, 2015 | BioSpace

    Marina Biotech, Inc. , a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported year-end corporate highlights and financial results for 2014. In addition, the Company also highlighted key patent grants that significantly expanded its intellectual property estate.

    Comment?

  12. Marina Biotech, Inc., Ink $50 Million R&D PactRead the original story

    Dec 17, 2014 | BioSpace

    Marina Biotech, Inc. , a leading nucleic acid-based drug discovery and development company focused on rare diseases, and MiNA Therapeutics Limited, the pioneer in RNA activation therapeutics, announced today that they have entered into a license agreement regarding the development and commercialization of small activating RNA based therapeutics utilizing MiNA's proprietary oligonucleotides and Marina's novel SMARTICLES nucleic acid delivery technology. MiNA will have full responsibility for the development and commercialization of any products arising under the Agreement and Marina Biotech will support pre-clinical and process development efforts.

    Comment?

  13. Marina Biotech and MiNA Therapeutics Announce License Agreement for...Read the original story w/Photo

    Dec 18, 2014 | Market Wire

    MiNA will have full responsibility for the development and commercialization of any products arising under the Agreement and Marina Biotech will support pre-clinical and process development efforts. Under terms of the Agreement, Marina Biotech could receive up to $50 million in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration.

    Comment?

  14. Marina Biotech, Inc. Reports That Licensee ProNAi Therapeutics, Inc....Read the original story

    Dec 9, 2014 | BioSpace

    Marina Biotech, Inc. , a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported that its licensee, ProNAi Therapeutics, reported that a number of patients with relapsed or refractory Non-Hodgkin's Lymphoma treated with its first DNAi -based therapeutic, PNT2258, achieved meaningful therapeutic outcomes and continue to exhibit durable clinical responses. PNT2258 is one of two nucleic acid-based therapeutics in clinical development which are formulated with Marina Biotech's proprietary SMARTICLES delivery technology.

    Comment?

  15. Marina Biotech: A Forgotten And Grossly Undervalued Game ChangerRead the original story w/Photo

    Jan 22, 2013 | Seeking Alpha

    Trading at less than a quarter of valuation of its closest peer that was acquired by Roche in August 2014, Marina Biotech is extremely undervalued. News in the RNA therapeutics sector continues to attract strong attention; most recently in Regulus Therapeutics' Phase I Hepatitis-C results.

    Comment?

  16. Marina Biotech: A Forgotten And Grossly Undervalued Game-ChangerRead the original story w/Photo

    Jan 22, 2013 | Seeking Alpha

    Trading at less than a quarter of valuation of its closest peer that was acquired by Roche in August 2014, Marina Biotech is extremely undervalued. News in the RNA therapeutics sector continues to attract strong attention; most recently in Regulus Therapeutics' phase I Hepatitis-C results.

    Comment?

  17. Marina Biotech, Inc. Reports That Partner Mirna Therapeutics, Inc....Read the original story

    Nov 19, 2014 | BioSpace

    Marina Biotech, Inc. , a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported that its partner, Mirna Therapeutics, presented interim safety and preliminary efficacy data from a multicenter, open-label Phase 1 clinical trial of MRX34. MRX34 is a microRNA34 mimic formulated in the Company's SMARTICLES delivery technology.

    Comment?

  18. Marina Biotech Reports That Partner Mirna Therapeutics Presented...Read the original story

    Nov 20, 2014 | Freshnews

    MRX34 is a microRNA34 mimic formulated in the Company's SMARTICLES delivery technology. The data show that MRX34 has a manageable safety profile in patients with advanced primary liver cancer , other solid tumors with liver metastasis, and hematological malignancies.

    Comment?

  19. Rosetta Genomics Ltd. And Marina Biotech, Inc. Initiate First...Read the original story

    Nov 18, 2014 | BioSpace

    Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, and Marina Biotech, Inc. , a leading nucleic acid-based drug discovery and development company focused on rare diseases, jointly announced the initiation of the first project under the Strategic Alliance the companies announced on April 2, 2014. The first project will be a clinical study conducted by Rosetta Genomics to identify novel microRNA candidates for the treatment of Duchenne Muscular Dystrophy .

    Comment?

  20. Marina Biotech, Inc. Announces Third Quarter 2014 Financial ResultsRead the original story

    Nov 18, 2014 | BioSpace

    Marina Biotech, Inc. , a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported financial results for the three months ended September 30, 2014.

    Comment?